This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
Enterovirus 71 vaccination as an addition to the routine immunisation programme was compared against no vaccination.
Location/setting
China/primary care.
Methods

Analytical approach:
The analysis was based on a decision model, with a lifetime horizon. The authors stated that it was conducted from the perspective of the third-party payer.
Effectiveness data:
The clinical inputs appear to have been from a selection of relevant sources, including country-specific administrative databases of disease surveillance. The baseline risk of disease-related health events was the key input for the model and was from Chinese databases and United Nations International Children's Emergency Fund (UNICEF) data. Vaccine efficacy was varied over a large range of values. Some assumptions were needed.
Monetary benefit and utility valuations:
The disutility weights were from a World Health Organization (WHO) publication that assessed the global burden of disease.
Measure of benefit:
Disability-adjusted life-years (DALYs) were the summary benefit measure.
Cost data:
The economic analysis included the costs of vaccination (vaccine acquisition and administration), treatment of sideeffects, and the in-patient and out-patient costs of the following health conditions: encephalitis, myocarditis, aseptic meningitis, pulmonary oedema, acute flaccid paralysis, hand foot and mouth disease, and herpangina. These costs were identified by an extensive search of the literature and from the US Healthcare Cost and Utilization Project (HCUP), Nationwide Inpatient Sample. US costs were adapted to the Chinese setting using a specific multiplier. The price year was 2010 and all costs were reported in Chinese yuan and US dollars ($).
